CADL
Neutral signalScored 2026-09-16 Drivers: fundamentals. Insiders: neutral. Moteurs : fondamentaux. Initiés : neutre.
Research, not advice.
À propos
Candel Therapeutics, Inc.
- Nom
- Candel Therapeutics, Inc.
- Secteur
- Healthcare
- Industrie
- Biotechnology
- Bourse
- NASDAQ
- Capitalisation
- $614.4M
- Employés
- 55
- PDG
- Paul-Peter Tak
- Site web
- https://www.candeltx.com
- Marché
- GNLXIMMXINABIOVAIPSCMGNX
Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical firm based in Needham, Massachusetts, dedicated to developing innovative immunotherapies for cancer patients. Its pipeline features CAN-2409, which is presently in Phase II clinical trials for pancreatic and lung cancers, and has progressed to Phase III for prostate cancer. This therapy also successfully completed Phase Ib/II trials for high-grade glioma. Furthermore, the company is advancing CAN-3110, an investigational therapy currently in Phase I clinical trials for recurrent glioblastoma. Established in 2003, the company operated as Advantagene, Inc. until November 2020, when it rebranded as Candel Therapeutics, Inc.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 280 245 titres (~3 160 783,32 $ US)
- Insiders
- Tak Paul Peter
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$3,244,783
Avg sell (VWAP, 90d window) $11.30 vs last close —
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
$3,244,783 of that total is under a Rule 10b5-1 plan. It is shown here and left out of the score.
- Last activity
- 2026-09-11
- Last synced
-
2026-09-17 09:54:31
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-09-11 | Tak Paul Peter | Sell · S · 10b5-1 | 59,379 | $10.46 | $620,891 | Form 4 |
| 2026-09-10 | Tak Paul Peter | Sell · S · 10b5-1 | 220,866 | $11.50 | $2,539,893 | Form 4 |
| 2026-08-17 | Tyagarajan Seshu | Sell · S · 10b5-1 | 7,000 | $12.00 | $84,000 | Form 4 |
Sales marked 10b5-1 are scheduled in advance and don't count toward the Quorum score. Les ventes marquées 10b5-1 sont planifiées à l'avance et ne pèsent pas dans le score Quorum.
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Signal
Neutral signalScored 2026-09-16 Drivers: fundamentals. Insiders: neutral. Moteurs : fondamentaux. Initiés : neutre.
CADL presents a deeply unfavorable risk/reward profile: despite promising FDA filing headlines for its prostate cancer program, the complete absence of revenue, persistent operating losses, and a non-viable business…
The first sentence of the analysis written for CADL on 2026-09-16 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Unavailable or mixed. – Insider: neutral. All sales (≈ $3.2M) were pre-planned Rule 10b5-1 trades, excluded from the score. No open-market buys or discretionary sales. – Initiés : neutre. Toutes les ventes (≈ $3.2M) sont sous plan 10b5-1 préétabli, exclues du score. Aucun achat ni vente discrétionnaire.
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Narrative Pulls against a bullish reading. Stored narrative reading is in the bearish band
- Timing Unavailable or mixed. No stored price series
- Financial indicators Supports a bullish reading. Current ratio 13.31 · operating margin 0.0%
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.0% | 0.0% | 0.0% | 100.0% | 100.0% | |
| Ebit Margin | 0.0% | 0.0% | 0.0% | -13668.8% | -28899.2% | |
| Ebitda Margin | 0.0% | 0.0% | 0.0% | -13046.4% | -28899.2% | |
| Operating Profit Margin | 0.0% | 0.0% | 0.0% | -27739.2% | -20580.8% | |
| Pretax Profit Margin | 0.0% | 0.0% | 0.0% | -15035.2% | -28899.2% | |
| Continuous Operations Profit Margin | 0.0% | 0.0% | 0.0% | -15035.2% | -28899.2% | |
| Net Profit Margin | 0.0% | 0.0% | 0.0% | -15035.2% | -28899.2% | |
| Bottom Line Profit Margin | 0.0% | 0.0% | 0.0% | -15035.2% | -28899.2% | |
| Current Ratio | 13.308 | 2.766 | 2.594 | 12.813 | 15.842 | |
| Quick Ratio | 13.308 | 2.766 | 2.594 | 12.813 | 15.842 | |
| Solvency Ratio | -0.510 | -1.337 | -1.300 | -0.585 | -1.441 | |
| Cash Ratio | 13.308 | 2.735 | 2.497 | 12.477 | 15.413 | |
| Price To Earnings Ratio | -7.847 | -4.989 | -1.122 | -18.008 | -4.094 | |
| Price To Earnings Growth Ratio | 0.134 | -0.152 | -0.001 | 0.190 | -0.066 | |
| Forward Price To Earnings Growth Ratio | 0.134 | -0.152 | -0.001 | 0.190 | -0.066 | |
| Price To Earnings Diluted Ratio | -7.847 | -4.989 | -1.122 | -18.008 | -4.094 | |
| Price To Earnings Diluted Growth Ratio | 0.134 | -0.152 | -0.001 | 0.190 | -0.066 | |
| Price To Book Ratio | 5.763 | 4.145 | 3.337 | 1.081 | 2.301 | |
| Price To Sales Ratio | 0.000 | 0.000 | 0.000 | 412.752 | 1,180.698 | |
| Price To Free Cash Flow Ratio | -7.692 | -10.168 | -1.226 | -1.577 | -6.136 | |
| Price To Operating Cash Flow Ratio | -7.810 | -10.174 | -1.242 | -1.642 | -6.643 | |
| Debt To Assets Ratio | 0.015 | 0.126 | 0.552 | 0.290 | 0.006 | |
| Debt To Equity Ratio | 0.037 | 0.203 | 1.786 | 0.478 | 0.009 | |
| Debt To Capital Ratio | 0.035 | 0.169 | 0.641 | 0.323 | 0.009 | |
| Long Term Debt To Capital Ratio | 0.027 | 0.038 | 0.493 | 0.304 | 0.009 | |
| Financial Leverage Ratio | 2.411 | 1.611 | 3.233 | 1.646 | 1.391 | |
| Working Capital Turnover Ratio | 0.000 | 0.000 | 0.000 | 0.002 | 0.002 | |
| Operating Cash Flow Ratio | -4.258 | -0.720 | -2.414 | -5.596 | -4.144 | |
| Operating Cash Flow Sales Ratio | 0.000 | 0.000 | 0.000 | -251.352 | -177.744 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.015 | 1.001 | 1.013 | 1.041 | 1.083 | |
| Debt Service Coverage Ratio | -13.736 | -4.347 | -2.993 | -7.508 | 0.000 | |
| Interest Coverage Ratio | -22.778 | -15.967 | -14.794 | -20.301 | 0.000 | |
| Short Term Operating Cash Flow Coverage Ratio | -86.092 | -2.731 | -3.851 | -67.713 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -20.121 | -2.006 | -1.504 | -1.378 | -39.675 | |
| Capital Expenditure Coverage Ratio | -65.266 | -1,688.938 | -74.932 | -24.224 | -12.108 | |
| Dividend Paid And Capex Coverage Ratio | -65.266 | -1,688.938 | -74.932 | -24.224 | -12.108 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -5.150 | -3.566 | -0.869 | -0.266 | -1.813 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 0.0% | 0.0% | ▼-40.0% |
| Ebit Margin | 0.0% | 0.0% | ▲8513.6% |
| Ebitda Margin | 0.0% | 0.0% | ▲8389.1% |
| Operating Profit Margin | 0.0% | 0.0% | ▲9664.0% |
| Pretax Profit Margin | 0.0% | 0.0% | ▲8786.9% |
| Continuous Operations Profit Margin | 0.0% | 0.0% | ▲8786.9% |
| Net Profit Margin | 0.0% | 0.0% | ▲8786.9% |
| Bottom Line Profit Margin | 0.0% | 0.0% | ▲8786.9% |
| Current Ratio | 13.308 | ▲10.542 | ▲3.843 |
| Quick Ratio | 13.308 | ▲10.542 | ▲3.843 |
| Solvency Ratio | -0.510 | ▲0.827 | ▲0.525 |
| Cash Ratio | 13.308 | ▲10.573 | ▲4.022 |
| Price To Earnings Ratio | -7.847 | ▼-2.859 | ▼-0.635 |
| Price To Earnings Growth Ratio | 0.134 | ▲0.286 | ▲0.113 |
| Forward Price To Earnings Growth Ratio | 0.134 | ▲0.286 | ▲0.113 |
| Price To Earnings Diluted Ratio | -7.847 | ▼-2.859 | ▼-0.635 |
| Price To Earnings Diluted Growth Ratio | 0.134 | ▲0.286 | ▲0.113 |
| Price To Book Ratio | 5.763 | ▲1.618 | ▲2.437 |
| Price To Sales Ratio | 0.000 | 0.000 | ▼-318.690 |
| Price To Free Cash Flow Ratio | -7.692 | ▲2.476 | ▼-2.333 |
| Price To Operating Cash Flow Ratio | -7.810 | ▲2.364 | ▼-2.308 |
| Debt To Assets Ratio | 0.015 | ▼-0.111 | ▼-0.183 |
| Debt To Equity Ratio | 0.037 | ▼-0.166 | ▼-0.466 |
| Debt To Capital Ratio | 0.035 | ▼-0.133 | ▼-0.200 |
| Long Term Debt To Capital Ratio | 0.027 | ▼-0.010 | ▼-0.147 |
| Financial Leverage Ratio | 2.411 | ▲0.800 | ▲0.353 |
| Working Capital Turnover Ratio | 0.000 | 0.000 | ▼-0.001 |
| Operating Cash Flow Ratio | -4.258 | ▼-3.538 | ▼-0.832 |
| Operating Cash Flow Sales Ratio | 0.000 | 0.000 | ▲85.819 |
| Free Cash Flow Operating Cash Flow Ratio | 1.015 | ▲0.015 | ▼-0.015 |
| Debt Service Coverage Ratio | -13.736 | ▼-9.389 | ▼-8.019 |
| Interest Coverage Ratio | -22.778 | ▼-6.811 | ▼-8.010 |
| Short Term Operating Cash Flow Coverage Ratio | -86.092 | ▼-83.361 | ▼-54.015 |
| Operating Cash Flow Coverage Ratio | -20.121 | ▼-18.115 | ▼-7.184 |
| Capital Expenditure Coverage Ratio | -65.266 | ▲1623.672 | ▲307.828 |
| Dividend Paid And Capex Coverage Ratio | -65.266 | ▲1623.672 | ▲307.828 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -5.151 | ▼-1.585 | ▼-2.818 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $299.2M | $274.9M | $42.5M | $51.6M | $147.6M | |
| Enterprise value | $181.4M | $185.8M | $29.9M | $4.3M | $65.5M | |
| EV / Sales | 0.00x | 0.00x | 0.00x | 34.69x | 524.04x | |
| EV / Op. cash flow | -4.74x | -6.87x | -0.87x | -0.14x | -2.95x | |
| EV / Free cash flow | -4.66x | -6.87x | -0.86x | -0.13x | -2.72x | |
| EV / EBITDA | -5.15x | -3.57x | -0.87x | -0.27x | -1.81x | |
| Net debt / EBITDA | 3.35x | 1.71x | 0.37x | 2.90x | 2.27x | |
| Current ratio | 13.31x | 2.77x | 2.59x | 12.81x | 15.84x | |
| Income quality | 1.00x | 0.49x | 0.90x | 1.67x | 0.61x | |
| Graham net-net | $1 | $2 | $0 | $1 | $3 | |
| Tax burden | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Interest burden | 105.9% | 103.9% | 107.3% | 110.0% | 100.0% | |
| Working capital | $110.7M | $66.3M | $22.6M | $66.3M | $79.6M | |
| Invested capital | $110.7M | $69.0M | $26.6M | $71.8M | $83.4M | |
| Return on assets | -30.5% | -51.6% | -92.1% | -23.9% | -40.5% | |
| Operating ROA | -41.6% | -45.1% | -64.1% | -41.3% | -40.4% | |
| Return on tangible assets | -30.5% | -51.6% | -92.1% | -23.9% | -40.5% | |
| Return on equity | -73.5% | -83.2% | -297.7% | -39.4% | -56.3% | |
| Return on invested capital | -41.4% | -41.8% | -105.4% | -47.3% | -30.7% | |
| Return on capital employed | -41.5% | -48.1% | -142.1% | -47.6% | -30.7% | |
| Earnings yield | -12.8% | -20.1% | -89.2% | -36.4% | -24.5% | |
| Free cash flow yield | -13.0% | -9.8% | -81.6% | -63.4% | -16.3% | |
| Capex / Op. cash flow | -1.5% | -0.1% | -1.3% | -4.1% | -8.3% | |
| Capex / Depreciation | 69.5% | 1.6% | 47.6% | 166.7% | 790.9% | |
| Capex / Sales | 0.0% | 0.0% | 0.0% | 1037.6% | 1468.0% | |
| SG&A / Sales | 0.0% | 0.0% | 0.0% | 11248.0% | 8538.4% | |
| R&D / Sales | 0.0% | 0.0% | 0.0% | 16629.6% | 12142.4% | |
| Stock comp / Sales | 0.0% | 0.0% | 0.0% | 1845.6% | 2370.4% | |
| Intangibles / Total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Days sales outstanding | 0d | 0d | 0d | 0d | 0d | |
| Days payables outstanding | 0d | 0d | 0d | 0d | 0d | |
| Operating cycle | 0d | 0d | 0d | 0d | 0d | |
| Cash conversion cycle | 0d | 0d | 0d | 0d | 0d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years
Employee count
Peer market caps
Recent news
- 2026-09-15 4 Prostate Cancer Drug Stocks to Watch During Awareness Month Pfizer, Novartis, Janux Therapeutics and Candel Therapeutics offer varied prostate-cancer exposure, with established drugs and clinical or regulatory catalysts.
- 2026-09-10 Candel Therapeutics Appoints Martine Zimmermann, PharmD, to its Board of Directors NEEDHAM, Mass., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced the appointment of Martine Zimmermann, PharmD, to the Company''s Board of Directors (Board) effective September 8, 2026.
- 2026-09-01 Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) NEEDHAM, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced that on August 31, 2026, the Compensation Committee of Candel''s Board of Directors (the Board) granted to two new employees, stock options to purchase an aggregate of 31,400 shares of the Company''s common stock, with a per share exercise price of $13.07.
- 2026-08-26 Candel Therapeutics to Present at September Investor Conferences NEEDHAM, Mass., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced that Paul Peter Tak, M.D.
- 2026-08-16 Are Biotech Stocks The ''Comeback Kid'' Of 2026? I Say Yes Biotech, especially small-cap names, is experiencing renewed optimism as macro and policy headwinds subside, driving sector-wide rallies. Stabilization at the FDA and a resurgence in M&A and IPO activity are restoring capital flows and investor confidence in biotech equities.
- 2026-08-13 Candel Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights NEEDHAM, Mass., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve outcomes for patients with cancer, today announced financial results for the second quarter ended June 30, 2026, and provided a corporate update.
- 2026-08-12 Candel Therapeutics Eyes 2026 Prostate Cancer Filing as Lung Study Ramps Up Candel Therapeutics NASDAQ: CADL is advancing two off-the-shelf viral immunotherapy candidates designed for local administration intended to generate systemic immune responses against tumors, Chief Scientific Officer Francesca Barone said at the Canaccord Genuity Growth Conference in Boston.
- 2026-08-07 Candel Therapeutics: Getting Closer, And Building Out More Paths Candel Therapeutics, Inc. remains a Buy as its lead asset, CAN-2409, advances toward FDA submission in prostate cancer with strong phase 3 data. CADL is well-capitalized, holding $194.8M in cash, providing runway into Q1 2028 and supporting pivotal trials in prostate and lung cancer. CAN-2409''s phase 3 prostate cancer trial, conducted under Special Protocol Assessment, positions CADL for a potentially smoother regulatory review.
- 2026-08-03 Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) NEEDHAM, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced that on July 31, 2026, the Compensation Committee of Candel''s Board of Directors (the Board) granted to three new employees, stock options to purchase an aggregate of 30,800 shares of the Company''s common stock, with a per share exercise price of $10.01.
- 2026-08-03 Candel Therapeutics to Present Extended Data from Phase 3 Results of Aglatimagene Besadenovec at ASTRO 2026 NEEDHAM, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced that an abstract was accepted for poster presentation at the 2026 American Society for Radiation Oncology (ASTRO) Annual Meeting, taking place September 26-30, 2026, in Boston, MA.